Macquarie Group LTD Concert Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$12.07 - $17.54 $24,140 - $35,080	-2,000 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$11.25 - $16.17 $257,625 - $370,293	-22,900 Reduced 91.97%	2,000 $25,000
Q3 2018 Nov 15, 2018	SELL	$12.82 - $17.88 $315,372 - $439,848	-24,600 Reduced 49.7%	24,900 $370,000
Q2 2018 Aug 14, 2018	BUY	$16.83 - $21.66 $395,504 - $509,010	23,500 Added 90.38%	49,500 $833,000
Q1 2018 May 11, 2018	BUY	$19.24 - $28.03 $500,239 - $728,780	26,000 New	26,000 $595,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.